Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228247 · ClinicalTrials.gov registry record · Phase 1
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
A Phase 1 study of Solid Tumors, Adult, sponsored by Hutchmed.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 147
- Enrollment target
- 11
- Study locations
NCT07228247 is a Phase 1 study of Solid Tumors, Adult that is actively recruiting participants, run by Hutchmed. The registered enrollment target is 147 participants, below the 231-participant average among 5 other Solid Tumors, Adult trials with a reported enrollment target (36% lower). The trial reports 11 study locations across 6 states.
The verdict
NCT07228247, a Phase 1 study of Solid Tumors, Adult, is actively recruiting participants, sponsored by Hutchmed.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 147 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.
Conditions Studied
Interventions
- DRUG HMPL-A251
Study Locations (11)
Other
- Peking University First Hospital - Beijing
- Hunan Cancer Hospital - Changsha
- Fujian Cancer Hospital - Fujian
- Sun Yat-sen University Cancer Center - Guangzhou
- The First Affiliated Hospital of Anhui Medical University - Hefei
- Henan Cancer Hospital - Zhengzhou
Colorado
- SCRI HealthONE - Denver
Florida
- BRCR Global - Plantation
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07228247
The ClinicalTrials.gov registry entry for NCT07228247 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 5 other Solid Tumors, Adult trials with a reported enrollment target (36% lower). The listed sponsor is Hutchmed, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors, Adult appearing as the primary indexed condition, and to 1 intervention - of which HMPL-A251 is the first listed.
NCT07228247 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Other, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT07228247 about?
NCT07228247 is a clinical study titled "A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors". This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.
What is the current status of trial NCT07228247?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2025-12-16. Estimated completion is 2028-12-31.
What conditions does trial NCT07228247 study?
This clinical trial studies the following conditions: Solid Tumors, Adult.
What interventions are being tested in trial NCT07228247?
The interventions under investigation include: HMPL-A251 (DRUG).
Who is sponsoring clinical trial NCT07228247?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07228247 being conducted?
This trial has 11 study locations across Colorado, Florida, New York, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
RECRUITING · Phase 1
-
Imaging of Solid Tumors Using FAP-2286
RECRUITING · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
RECRUITING · Phase 1
-
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.